HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and maintained a $50 price target.
August 12, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics and maintained a $50 price target.
The reiteration of a Buy rating and the maintenance of a $50 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100